瑞博西利

{{Infobox drug
| IUPAC_name = 7-Cyclopentyl-N,N-dimethyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide
| image = Ribociclib skeletal.svg
| alt =
| caption =

| pronounce =
| tradename = Kisqali
| Drugs.com =
| MedlinePlus = a617008
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_US =
| pregnancy_category=
| routes_of_administration = By mouth (tablets)
| legal_AU =
| legal_AU_comment =
| legal_CA =
| legal_DE =
| legal_NZ =
| legal_UK =
| legal_US = Rx-only
| legal_UN =
| legal_status =

| bioavailability = Unknown
| protein_bound = ~70%
| metabolism = Liver (CYP3A4)
| metabolites =
| onset =
| elimination_half-life = 32.0 (29.7–54.7) hrs
| duration_of_action=
| excretion = 69% feces, 23% urine

| CAS_number = 1211441-98-3
| class =
| ATCvet =
| ATC_prefix = L01
| ATC_suffix = XE42
| PubChem = 44631912
| DrugBank = DB11730
| ChemSpiderID = 30798107
| UNII = TK8ERE8P56
| KEGG = D10883
| ChEMBL = 3545110
| synonyms = LEE 011

| chemical_formula =
| C=23 | H=30 | N=8 | O=1
| molecular_weight =
| smiles = CN(C)C(=O)c1cc2cnc(nc2n1C3CCCC3)Nc4ccc(cn4)N5CCNCC5
| StdInChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)
| StdInChIKey = RHXHGRAEPCAFML-UHFFFAOYSA-N
}}
瑞博西利（）商品名擊癌利（KISQALI）是一種CDK4/6抑制劑類型的乳腺癌藥物，由Astex和诺华制药研发。可使用的對象為：賀爾蒙接受體陽性、HER2陰性患者，以及停經後晚期乳腺癌患者。

参考文献